Ambiante Health & Wellness review

Ambiante advertises concierge-style support and a broad compounded peptide catalog with starting prices. Obtain the treatment and monitoring quote, pharmacy assignment and cancellation terms; the breadth of a menu does not establish clinical benefit.

Ambiante Health & Wellness LLC operates a telehealth platform connecting patients with independent providers. Its broad catalog includes compounded sermorelin and multi-peptide stacks, with advertised starting prices. Confirm the clinician, pharmacy, state eligibility and monitoring for the proposed plan.

The service advertises a dedicated provider, messaging and check-ins. Its terms identify a technology platform connecting patients with independent clinicians and pharmacies. Confirm required labs and state eligibility. A medical-decline refund provision does not establish that a card is never charged before approval.

The catalog advertises sermorelin from $199/month and peptide stacks from $299/month; final treatment cost requires a consultation quote. Current Health Passport pricing remains unconfirmed. Initial prescription cancellation requires both a request within 24 hours and no receipt by the provider network. The terms separately list unshipped, declined, wrong, damaged or unsafe orders as refund situations; dispensed or delivered medication is nonrefundable. Confirm which clause governs your order.

Compounded; not FDA-approved. Prescription required only if a licensed provider finds it appropriate. The peptide pages say products are compounded in a U.S. pharmacy, and every plan lists compounded medication, but the pharmacy is not named, and the site's own footer disclaimer says prescribed medications are "FDA-approved products", which contradicts the rest of the site. Ask which applies to your prescription. On the evidence: sermorelin and the other growth-hormone-axis peptides have a genuine, well-described mechanism and thin long-term human outcome data. BPC-157, TB-500 and the recovery stacks built on them have essentially no controlled human outcome trials. NAD⁺ by injection has no controlled outcome trials; the oral precursors NR and NMN are the forms with human data, and that data shows a raised blood NAD⁺ level rather than a demonstrated clinical benefit. The GLP-1 microdose protocol has thinner trial evidence than standard dosing and should be expected to do less. Individual results vary.